Montefiori DC - Search Results

1

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD. Shen X, et al. Among authors: montefiori dc. J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4. J Virol. 2009. PMID: 19193787 Free PMC article.

2

Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.

Montefiori DC, Zhou IY, Barnes B, Lake D, Hersh EM, Masuho Y, Lefkowitz LB Jr. Montefiori DC, et al. Virology. 1991 Jun;182(2):635-43. doi: 10.1016/0042-6822(91)90604-a. Virology. 1991. PMID: 1708933

3

Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Javaherian K, Langlois AJ, Montefiori DC, Kent KA, Ryan KA, Wyman PD, Stott J, Bolognesi DP, Murphey-Corb M, Larosa GJ. Javaherian K, et al. Among authors: montefiori dc. J Virol. 1994 Apr;68(4):2624-31. doi: 10.1128/JVI.68.4.2624-2631.1994. J Virol. 1994. PMID: 7511176 Free PMC article.

4

Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.

Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR. Montefiori DC, et al. Virology. 1994 Nov 15;205(1):82-92. doi: 10.1006/viro.1994.1622. Virology. 1994. PMID: 7526538

5

Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. National Institutes of Health AIDS Vaccine Clinical Trials Networks.

Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM. Montefiori DC, et al. J Infect Dis. 1994 Aug;170(2):429-32. doi: 10.1093/infdis/170.2.429. J Infect Dis. 1994. PMID: 8035031

6

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS. Montefiori DC, et al. J Infect Dis. 1996 Jan;173(1):60-7. doi: 10.1093/infdis/173.1.60. J Infect Dis. 1996. PMID: 8537683

7

The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.

Palker TJ, Muir AJ, Spragion DE, Staats HF, Langlois A, Montefiori DC. Palker TJ, et al. Among authors: montefiori dc. Virology. 1996 Oct 15;224(2):415-26. doi: 10.1006/viro.1996.0548. Virology. 1996. PMID: 8874502 Free article.

8

Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).

Zhou J, Montefiori DC. Zhou J, et al. Among authors: montefiori dc. Virology. 1996 Dec 1;226(1):13-21. doi: 10.1006/viro.1996.0623. Virology. 1996. PMID: 8941318 Free article.

9

A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3.

Hirsch V, Adger-Johnson D, Campbell B, Goldstein S, Brown C, Elkins WR, Montefiori DC. Hirsch V, et al. Among authors: montefiori dc. J Virol. 1997 Feb;71(2):1608-20. doi: 10.1128/JVI.71.2.1608-1620.1997. J Virol. 1997. PMID: 8995688 Free PMC article.

10

Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.

Zhou JY, Montefiori DC. Zhou JY, et al. Among authors: montefiori dc. J Virol. 1997 Mar;71(3):2512-7. doi: 10.1128/JVI.71.3.2512-2517.1997. J Virol. 1997. PMID: 9032392 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

762 results

Search Page